A therapeutic review document provides a rapid collation of published literature evidence to support DTC decision making. It provides a critical evaluation of the literature but does not make recommendations about place in therapy of the medicine in question. It can be produced much more quickly than a position statement, and is therefore of value to DTCs in managing formulary decisions.
-
Adalimumab in inflammatory bowel disorders
March 2008
-
Antiplatelet Therapies: Current Issues
November 2009 (update)
-
Drugs for the treatment of secondary hyperparathyroidism and hyperphosphataemia
June 2007
-
Infliximab in Crohn's Disease
November 2006
-
Infliximab in Ulcerative Colitis
August 2007
-
Intravenous bisphosphonates in osteoporosis: Key Questions
November 2010
See also other guidance or review documents: